Pharmacological targeting of mitochondrial dysfunction in Parkinson’s disease: approaches and perspectives
Mitochondrial dysfunction has been widely implicated in the neuronal degeneration in Parkinson’s disease (PD). Mitochondria-targeted protective compounds that prevent or minimise a wide range of mitochondrial defects constitute potential therapeutic strategies in the prevention and treatment of neuronal degeneration in PD.
This review discusses the latest findings in this field obtained in PD patients and in animal and cellular models of PD with focus on the effects of pharmacological agents on mitochondrial biogenesis, fission, fusion, mitophagy machinery, and transcription of endogenous cytoprotective antioxidant enzymes. We also present data concerning the technologies for research and screening of novel bioactive molecules to target mitochondrial dysfunction in Parkinson’s disease.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!